Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The Department of Health and Human Services has released Positive Spin, a digital educational tool that uses personal storytelling to promote the importance of getting people with HIV into treatment.
The health IT needs of patient-centered medical homes must evolve from digitized patient record repositories into interoperable electronic collaboration platforms to further develop care coordination efforts, according to a study published in Journal of the American Medical Informatics Association.
Partners HealthCare has been awarded a grant from the Robert Wood Johnson Foundation for the development of an 'Engagement Engine' to support the sustained use of health and activity trackers and engagement in physical activity, in order to improve health outcomes in the general population.
Almost half (46 percent) of healthcare professionals plan to incorporate smartphone apps into their practices within the next five years, according to a survey from the Research Now Group.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
